Changes in Hong Kong stocks | Cansino Biotech (06185) rose nearly 6% and the 24-valent pneumococcal polysaccharide conjugate vaccine was approved for clinical trials

The Zhitong Finance App learned that Cansino Biotech (06185) rose by nearly 6%. As of press release, it had risen 4.02% to HK$38.8, with a turnover of HK$30.97 million.

According to the news, Cansino Biotech announced that the 24-valent pneumococcal polysaccharide conjugate vaccine (CRM197/tetanus toxin, “PCV24” for short) independently developed by the company has officially obtained the “Drug Clinical Trial Approval Notice” issued by the State Drug Administration and approved for clinical trials. As of the disclosure date, there are no 24-valent pneumococcal conjugate vaccine products on the domestic and foreign markets.

According to the announcement, PCV24 has completed the development and confirmation of 24 serotype purified polysaccharides, polysaccharide protein conjugate stock solution production processes, and finished product prescriptions, covering the main popular serotypes of pneumococcal bacteria, and using covalent binding of polysaccharide antigens to protein carriers and dual carrier technology. It is intended to be suitable for vaccination of people aged 2 months (minimum 6 weeks) to prevent infectious diseases caused by 24 pneumococcal serotypes. PCV24 further promotes the development of high-cost pneumococcal conjugate vaccines based on the company's existing technology accumulation. The company said that this approval has further enriched and perfected the company's R&D pipeline in the field of pneumococcal conjugate vaccines.